Nasdaq · CIK 0001279704
CLRB Cellectar Biosciences, Inc.
Insider trading from SEC Form 4. Last filing Dec 16, 2025. Close $1.45 on Oct 9, 2026, +4% from the 52-week low and -71% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
8
with a Form 4 at this company
Price and insider trades, last year
CLRBOct 9, 2026 · close 1.45
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Cellectar Biosciences, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 35Weak | John Neis director sell | $732 198 shares | -95% | +28% from low-74% from high | |
| 75Notable | James Caruso V Chief Executive Officer buy | $50k 10,000 shares | +611% | 0% from low-93% from high | |
| 65Notable | Chad J Kolean Chief Financial Officer buy | $25k 5,000 shares | +353% | 0% from low-93% from high | |
| 70Notable | Jarrod Longcor Chief Operating Officer buy | $50k 10,000 shares | +361% | 0% from low-93% from high | |
| 30Weak | Jarrod Longcor Chief Operating Officer buy | $8,400 30,000 shares | +56% | - |
Transactions
The last 16 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 12, 2025 | John Neis director | SOpen-market sale Common Stockindirect: See Footnote | -198 | $3.70 | $732 | 10 | Dec 16, 2025 |
| Jul 2, 2025 | James Caruso V Chief Executive Officer | POpen-market purchase Common Stock | +10,000 | $4.99 | $50k | 11,638 | Jul 3, 2025 |
| Jul 2, 2025 | Chad J Kolean Chief Financial Officer | POpen-market purchase Common Stock | +5,000 | $4.99 | $25k | 6,418 | Jul 3, 2025 |
| Jul 2, 2025 | Jarrod Longcor Chief Operating Officer | POpen-market purchase Common Stock | +10,000 | $4.99 | $50k | 12,768 | Jul 3, 2025 |
| Jul 2, 2025 | James Caruso V Chief Executive Officer | POpen-market purchase Warrantsderivative | +10,000 | $0.01 | $100 | 10,000 | Jul 3, 2025 |
| Jul 2, 2025 | Chad J Kolean Chief Financial Officer | POpen-market purchase Warrantsderivative | +5,000 | $0.01 | $50 | 5,000 | Jul 3, 2025 |
| Jul 2, 2025 | Jarrod Longcor Chief Operating Officer | POpen-market purchase Warrantsderivative | +10,000 | $0.01 | $100 | 10,000 | Jul 3, 2025 |
| Jan 10, 2025 | Jarrod Longcor Chief Operating Officer | POpen-market purchase Common Stock | +30,000 | $0.28 | $8,400 | 83,141 | Mar 12, 2025 |
| Feb 14, 2025 | James Caruso V President and CEO | AGrant or award Stock option (right to buy)derivative | +900,000 | $0.00 | $0 | 900,000 | Feb 18, 2025 |
| Feb 14, 2025 | Asher Chanan-Khan director | AGrant or award Stock option (right to buy)derivative | +60,000 | $0.00 | $0 | 60,000 | Feb 18, 2025 |
| Feb 14, 2025 | Frederick W Driscoll director | AGrant or award Stock option (right to buy)derivative | +60,000 | $0.00 | $0 | 60,000 | Feb 18, 2025 |
| Feb 14, 2025 | Chad J Kolean Chief Financial Officer | AGrant or award Stock option (right to buy)derivative | +290,000 | $0.00 | $0 | 290,000 | Feb 18, 2025 |
| Feb 14, 2025 | Jarrod Longcor Chief Operating Officer | AGrant or award Stock option (right to buy)derivative | +500,000 | $0.00 | $0 | 500,000 | Feb 18, 2025 |
| Feb 14, 2025 | Stefan Loren director | AGrant or award Stock option (right to buy)derivative | +60,000 | $0.00 | $0 | 60,000 | Feb 18, 2025 |
| Feb 14, 2025 | John Neis director | AGrant or award Stock option (right to buy)derivative | +60,000 | $0.00 | $0 | 60,000 | Feb 18, 2025 |
| Feb 14, 2025 | Douglas J Swirsky director | AGrant or award Stock option (right to buy)derivative | +90,000 | $0.00 | $0 | 90,000 | Feb 18, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- James Caruso VChief Executive Officer
- Asher Chanan-Khandirector
- Frederick W Driscolldirector
- Chad J KoleanChief Financial Officer
- Jarrod LongcorChief Operating Officer
- Stefan Lorendirector
- John Neisdirector
- Douglas J Swirskydirector, cfo, officer
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.